Axovant Gene Therapies Ltd. (AXGT)

Home » Stocks » AXGT

Nov 13, 2020 - Stock symbol was changed to SIOX

Stock Price: $2.10 USD 0.00 (0.00%)

Updated Nov 12, 2020 4:00 PM EST

• Overview
• News
• Financials

Key Info

Market Cap	84.71M
Revenue (ttm)	n/a
Net Income (ttm)	-53.17M
Shares Out	40.34M
EPS (ttm)	-1.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	Nov 12, 2020
Last Price	$2.10
Previous Close	$2.10
Change ($)	0.00
Change (%)	0.00%
Day's Open	-
Day's Range	2.07 - 2.17
Day's Volume	0
52-Week Range	1.41 - 6.12

More Stats

Market Cap	84.71M
Enterprise Value	29.76M
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	40.34M
Float	24.37M
EPS (basic)	-1.90
EPS (diluted)	-1.78
FCF / Share	-1.47

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	1.44M
Short Ratio	0.65
Short % of Float	5.91%
Beta	1.58

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	n/a
PB Ratio	1.69
Revenue	n/a
Operating Income	-51.45M
Net Income	-53.17M
Free Cash Flow	-63.44M

Net Cash	54.95M
Net Cash / Share	1.36
Gross Margin	n/a
Operating Margin	n/a
Profit Margin	n/a
FCF Margin	n/a
ROA	-37.29%
ROE	-120.92%
ROIC	-3,363.20%

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy	5
Overweight	1
Hold	1
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: Buy

Price Target

$8.42*

(300.95% upside)

Low

7.00

Current: $2.10

High

12.50

Target: 8.42

*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow | Ratios

Year	2019	2018	2017	2016	2015	2014
Revenue	-	-	-	-	-	-
Operating Income	-69.17	-127	-213	-180	-133	-21.05
Net Income	-72.63	-129	-222	-181	-133	-21.05
Shares Outstanding	24.81	16.10	13.42	12.39	11.81	2.00
Earnings Per Share	-2.93	-8.02	-16.51	-14.56	-11.28	-10.56
Operating Cash Flow	-67.47	-134	-190	-112	-53.35	-0.68
Capital Expenditures	-0.26	-0.20	-4.28	-0.11	-0.09	-0.01
Free Cash Flow	-67.73	-134	-195	-112	-53.44	-0.69
Cash & Equivalents	80.75	107	154	213	276	-
Total Debt	16.39	44.18	52.68	51.44	-	-
Net Cash / Debt	64.36	62.82	102	161	276	-
Assets	93.68	123	161	223	282	1.12
Liabilities	32.12	66.49	89.50	97.70	15.76	8.87
Book Value	61.56	56.21	71.29	125	267	-7.75

Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name	Axovant Gene Therapies Ltd.
Country	United Kingdom
Employees	38
CEO	Pavan Cheruvu

Stock Information

Ticker Symbol	AXGT
Stock Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
Unique Identifier	NASDAQ: AXGT

Description

Axovant Gene Therapies, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Sciences Ltd. and changed its name to Axovant Gene Therapies Ltd. in March 2019. Axovant Gene Therapies Ltd. was founded in 2014 and is based in London, the United Kingdom.